Navigation Links
AxoGen, Inc. Announces Changes to Board of Directors
Date:8/25/2014

Alachua, FL (PRWEB) August 25, 2014

AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused on the peripheral nerve repair market, reported today that John McLaughlin, President and Chief Executive Officer of PDL BioPharma, Inc. has resigned from AxoGen’s Board of Directors.

Mr. McLaughlin joined AxoGen’s Board in 2012 as part of the Revenue Interest Purchase Agreement between AxoGen and PDL. At this time, PDL is not appointing a replacement for Mr. McLaughlin. As a result, the number of Directors has been reduced from eight to seven.

“It has been a great honor and pleasure to serve on the AxoGen Board. During the past two years, AxoGen has made great strides including 47% sales growth in the most recently reported quarter. AxoGen is an impressive company with medically important products that are of increasing commercial significance, an experienced management team whose execution is creating and will continue to create shareholder value, and a Board of Directors composed of knowledgeable and successful industry and healthcare veterans dedicated to the company’s success,” said Mr. McLaughlin. “I look forward to closely following the Company’s future development.”

AxoGen Board Chairman Jamie Grooms commented, “AxoGen continues to drive a paradigm change in the way surgical nerve repair is performed. During John’s tenure the Company has generated double digit growth and achieved many significant milestones. We would like to extend our sincere gratitude to John for his service to the Board, and his insights and leadership. In addition, we would like to thank PDL for its continued support of our development.”

About AxoGen, Inc.
AxoGen (NASDAQ: AXGN) is a leading medical technology company dedicated to peripheral nerve repair. AxoGen’s portfolio of regenerative medicine products is available in the United States, Canada and several other countries and includes Avance® Nerve Graft, the only off-the-shelf commercially available processed nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard® Nerve Connector, a porcine submucosa extracellular matrix (“ECM”) coaptation aid for tensionless repair of severed nerves, and AxoGuard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments.

Avance® Nerve Graft is processed in the United States by AxoGen. AxoGuard® Nerve Connector and AxoGuard® Nerve Protector are manufactured in the United States by Cook Biotech Incorporated, and are distributed worldwide exclusively by AxoGen. AxoGen maintains its corporate offices in Alachua, Florida and is the parent of its wholly owned operating subsidiary, AxoGen Corporation.

Cautionary Statements Concerning Forward-Looking Statements

This Press Release contains "forward-looking" statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations or predictions of future conditions, events or results based on various assumptions and management's estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as "expects", "anticipates", "intends", "plans", "believes", "seeks", "estimates", "projects", "forecasts", "continue", "may", "should", "will" variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include, without limitation, statements regarding our growth, our product development and product potential. The forward-looking statements are subject to risks and uncertainties, which may cause results to differ materially from those set forth in the statements. Forward-looking statements in this release should be evaluated together with the many uncertainties that affect AxoGen's business and its market, particularly those discussed in the risk factors and cautionary statements in AxoGen's filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made, and, except as required by law, AxoGen assumes no responsibility to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Read the full story at http://www.prweb.com/releases/2014/08/prweb12118555.htm.


'/>"/>
Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related medicine news :

1. AxoGen, Inc. to Present at the Wedbush 2014 Life Sciences Management Access Conference
2. AxoGen, Inc. Reports 47% Second Quarter Revenue Growth
3. AxoGen, Inc. to Report Second Quarter Financial Results on August 4, 2014
4. AxoGen, Inc. To Open New Distribution Facility in Burleson, TX
5. AxoGen, Inc. to Sponsor Surgeon Education Programs on Peripheral Nerve Surgery at American Society for Surgery of the Hand 2013
6. AxoGen, Inc. Announces Exercise of Over-Allotment Option
7. AxoGen, Inc. Closes $18 Million Offering and Moves to NASDAQ
8. AxoGen, Inc. Announces Pricing of $18 Million Underwritten Offering and Uplisting to NASDAQ
9. AxoGen, Inc. to Present at the Wedbush 2013 Life Sciences Management Access Conference
10. AxoGen, Inc. Reports Second Quarter 2013 Financial Results
11. AxoGen, Inc. Announces Presentation of Avance® Nerve Graft Data at the 18th Federation of European Societies for Surgery of the Hand Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... IL (PRWEB) , ... September 22, 2017 , ... Pullano ... attorney Richard L. Pullano has been selected to serve as President of ... 50th President at the Installation and Award Dinner hosted by the NSBA at the ...
(Date:9/22/2017)... ... September 22, 2017 , ... First Choice Emergency Room ... one year anniversary of its Houston-Fallbrook facility. , “We are honored to ... Director of First Choice Emergency Room Houston-Fallbrook. “It has been a pleasure serving ...
(Date:9/22/2017)... ... ... “Fruit of the Spirit: “Love””: a delightful adventure of two friends who play ... Spirit: “Love”” is the creation of published author, Halimah Jones, who was born and ... an avid writer, her inspiration for “Fruit of the Spirit: “Love”” blossomed from her ...
(Date:9/22/2017)... , ... September 22, 2017 , ... ... fertility and create life. Although frozen embryos have a slight statistical advantage for ... “Egg freezing is a wonderful opportunity for women undergoing medical treatment or who ...
(Date:9/21/2017)... FL (PRWEB) , ... September 21, 2017 , ... 38-Year-Old ... Aesthetic Surgery Center in Naples, Florida is pleased to announce that Plastic Surgeon Kiranjeet ... Top 40 Under 40 is an annual award that was started in ...
Breaking Medicine News(10 mins):
(Date:9/5/2017)... 5, 2017  Xyntek Inc. has announced another milestone in their continued growth ... to meet the growing demands of customer engagements regionally.  ... Xyntek's new Midwest office is located at 318 West Adams Street, Suite ... Xyntek's ... ...
(Date:9/5/2017)... , Sept. 5, 2017  Just 18 months ... Insight is pleased to announce the appointment of three ... Tammy Wynne , Dominic Jones-Phillips and ... industry. Tammy ... team of market access writers. She has over ten ...
(Date:9/1/2017)... Sept. 1, 2017 Michael Penna , ... , highlights opportunities for growth in his response to ... Marlin Equity is seeking a buyer for eMDs. Penna,s ... 22-year-old healthcare solutions Value Added Reseller and national leader ... "As the healthcare market continues to ...
Breaking Medicine Technology: